Ischemia in collateral-dependent myocardium: effects of nifedipine and diltiazem in man

G Pupita1, D Mazzara, M Centanni

  • 1Institute of Patologia Medica, University of Ancona, Italy.

Insights

Nifedipine and diltiazem effectively increase exercise tolerance in patients with collateral-dependent myocardium by improving blood flow. These calcium channel blockers enhance myocardial perfusion, offering a therapeutic benefit for angina patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Myocardial ischemia can occur at variable thresholds in patients with angina.
  • Collateral circulation plays a crucial role in supplying blood to ischemic areas of the heart.

Purpose of the Study:

  • To evaluate the efficacy of nifedipine and diltiazem in augmenting blood flow to collateralized myocardium in humans.
  • To compare the effects of nifedipine, diltiazem, and nitroglycerin on exercise-induced ischemia.

Main Methods:

  • Nine patients with complete coronary occlusion supplied by collaterals underwent exercise tests.
  • Pharmacological interventions included sublingual nifedipine (10 mg), oral diltiazem (120 mg), and sublingual nitroglycerin (0.5 mg).
  • Time to 1 mm ST segment depression served as the primary endpoint for ischemia.

Main Results:

  • Both nifedipine and diltiazem significantly increased the time to ischemic threshold (p < 0.01) without altering heart rate or rate-pressure product at this point.
  • Submaximal rate-pressure products were reduced by both nifedipine and diltiazem.
  • Nitroglycerin improved the time to ischemic threshold and increased heart rate and rate-pressure product.

Conclusions:

  • Nifedipine and diltiazem can improve blood flow to collateral-dependent myocardium in patients with angina.
  • These medications enhance exercise tolerance by delaying the onset of ischemia.
  • The findings support the use of these agents in managing patients with specific types of coronary artery disease.

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Antianginal Drugs: Nitrates and &#946;-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...